News | March 26, 2010

More Research Needed for Best Treatment of Multivessel Disease During STEMI

March 26, 2010 – Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-elevated myocardial infarction (STEMI) undergo multivessel primary percutaneous coronary intervention (PCI), despite recommendations from the American College of Cardiology and the American Heart Association to intervene on only the culprit vessel.

Those patients undergoing multivessel intervention experience higher unadjusted morbidity/mortality than those patients undergoing single vessel PCI. However, multivessel PCI was not a significant predictor of mortality once comorbid conditions were controlled in the regression model. These are among the findings of new research presented by Aaron D. Kugelmass, M.D., Baystate Medical Center, Springfield, Mass., at the American College of Cardiology's Scientific Sessions 2010 in Atlanta.

According to the study, STEMI patients undergoing multivessel PCI were more likely to be male, experience cardiogenic shock and have a drug-eluting stent. They also experience increased unadjusted in-hospital mortality, are more likely to experience acute renal failure, and have a lower incidence of coronary artery bypass graft surgery (CABG) than those undergoing single vessel PCI.

The research, funded and conducted by Cardiac Data Solutions, studied data on Medicare beneficiaries (MB) with a primary diagnosis of STEMI (first diagnosis code) that underwent a PCI during hospitalization between Oct. 1, 2006 and Sept. 30, 2007 and included 24,189 MB.

The study compared the following clinical outcomes between the MB undergoing single-vessel versus multivessel PCI:

• Acute renal failure
• New-onset hemodialysis
• Any vascular complication
• Observed mortality
• Expected mortality
• Stent type and usage

"The study supports the current recommendations that STEMI patients undergo culprit vessel PCI only, however, prospective assessment of this question is needed to identify the best treatment strategy for patients with STEMI and multivessel CAD," said April Simon, RN, MSN, president of Cardiac Data Solutions and one of the researchers.

Other researchers included: Phillip P. Brown, cardiovascular surgeon (retired) and past chairman, department of surgery, Centennial Medical Center; David J. Cohen, M.D., interventional cardiologist and director, cardiovascular research, Mid America Heart Institute, St. Luke's Hospital; Matthew R. Reynolds, M.D., electrophysiologist and director, Economics and Quality of Life Assessment Group, Harvard Clinical Research Institute; and Steven D. Culler, Ph.D., associate professor, Rollins School of Public Health, Emory University.

Cardiac Data Solutions provides consultation services, data analysis, clinical benchmarks, management tools, research support services and leadership training to hospitals, physicians, payors, manufacturers and the financial community.

For more information: http://tinyurl.com/ycue7xb, www.cardiacdatasolutions.com/cds/jsp/documents/Multi-Vessel%20Primary%20PCI%20Avisable%20%20Differences%20in%20Clinical%20Outcomes%20amongv4%20%20%20%20%20.pdf


Related Content

News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
News | Cardiovascular Clinical Studies

May 2, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...

Home May 02, 2024
Home
News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
Subscribe Now